AUG 29, 2019 8:20 AM PDT

Can FDA Approved Ketamine Drug Spravato Really Treat Depression?

WRITTEN BY: Annie Lennon

President Trump is allegedly in support of a new drug to combat depression. He even urged the Department of Veterans Affairs to purchase it and “get as much of it as they can” (Kelly: 2019). Known as esketamine and marketed as Spravato, although it was approved by the Food and Drug Administration (FDA) in March, some uncertainties remain over its efficacy and long term effects. 

Produced by a Johnson & Johnson subsidiary called Janssen, esketamine is the first new type of drug to treat severe depression in around three decades (Amin: 2019). Over the last few months, it has earned a reputation for providing fast relief from depressive symptoms. But how? Whereas popular antidepressant drugs such as Zoloft and Wellbutrin target serotonin and norepinephrine neurotransmitters to activate glutamate transmitters, they usually take weeks or even months to come to effect. As esketamine targets glutamate neurotransmitters directly however, relief from depressive symptoms can be felt within just days or hours (Palo Alto Mind Body: 2019). 

The development of the drug comes after research looking at the positive effects of ketamine on mice exposed to corticosterone, a stress hormone, in their drinking water. Introduction of this hormone was shown to destroy dendritic spines in their prefrontal cortex, thus reducing brain activity and causing depressive behavior. After a single dosage of ketamine however, these brain cells were repaired, and depressive behaviors disappeared (Mellor: 2019). Given these findings and earlier research on ketamine’s efficacy in treating human depression too, researchers began to study the drug more closely. 

Despite such reports on ketamine’s positive effects however, many physicians remain cautious on the usage of ketamine-derived drug Spravato. This comes as the drug’s approval by the FDA seems to have taken some shortcuts. Normally, drugs need to have undergone at least two successful clinical trials to demonstrate their efficacy, and gain approval. In the case of Spravato though, Janssen only provided one successful short-term, double-blind trial; two of its other trials falling short in efficacy (Kaiser Health News: 2019). 

Moreover, in their only positive trial, participants taking Spravato alongside popular antidepressants only experienced a 4-point improvement on a 60-point scale of symptoms of depression compared to those on the placebo treatment (Canuso: 2018). Adding to this, during their three studies six patients died, including three by suicide. Although these deaths were dismissed by the FDA as unrelated to the trials, according to Dr. Wesley Boyd, a psychiatrist at Cambridge Health Alliance, “The clinical trials of esketamine were completely underwhelming...I'm open to giving esketamine consideration, but given the data we have and its high cost, there are other drugs and therapies we can maximize first (Kelly: 2019).”

Adding to these concerns is the little data available on the drug’s long term effects, as well as its effects on different demographics. For example, the trials conducted by Jenssen were not conducted on those over 65- despite the prevalence of depression among this community. (ibid.).  Although long-term studies are currently ongoing, its overall efficacy remains unknown, even if it may be able to relieve some depressive symptoms along the way. 

To conclude, although when taken alongside popular antidepressants Spravato may be able to relieve some depressive symptoms, its limited efficacy from its trials shows that it is probably not a “wonder drug”. This comes especially when considering the uncertainty of both its risks and long term effects, as well as how it interacts with different population demographics. 


 

Sources 

 

Kelly, Dr. Lauren et al.: ABC News 

Amin, Nouran: Labroots

Palo Alto Mind Body

Mellor, Joe: The London Economic 

Kaiser Health News: The Daily Beast 

Canuso, CM et al.: Pub Med

 

 

About the Author
  • Annie graduated from University College London and began traveling the world. She is currently a writer with keen interests in genetics, psychology and neuroscience; her current focus on the interplay between these fields to understand how to create meaningful interactions and environments.
You May Also Like
JAN 14, 2020
Drug Discovery & Development
JAN 14, 2020
Can Silica Treat Obesity and Diabetes?
Silica particles, specifically ‘mesoporous silica particles (MSPs)’ are engineered molecular traps that may provide a breakthrough treatment op...
JAN 20, 2020
Cell & Molecular Biology
JAN 20, 2020
Using Modified Red Blood Cells As a Drug Delivery System
For a drug to be effective, it has to get to the right place to exert its impact....
JAN 21, 2020
Cell & Molecular Biology
JAN 21, 2020
Repurposing Existing Drugs to Treat Cancer
Drugs have to be rigorously tested before they can be offered to patients, so it can be much easier to find more than one application for a medication....
FEB 21, 2020
Health & Medicine
FEB 21, 2020
Frequent Cannabis Use Could Affect Driving Safety
A new study suggests that heavy marijuana users have the potential to be dangerous drivers. However, hazardous driving appears to be isolated to users who ...
MAR 07, 2020
Drug Discovery & Development
MAR 07, 2020
Single Trip on Magic Mushrooms Boosts Mindfulness
According to new research, a single trip from magic mushrooms is enough for people to experience long-term increases in mindfulness and openness. Mindfulne...
MAR 19, 2020
Drug Discovery & Development
MAR 19, 2020
Could a 1949 Malaria Drug Treat COVID-19?
In the race to halt the current coronavirus pandemic, scientists, health experts and even Elon Musk are considering chloroquine, a drug that has been used ...
Loading Comments...